This message contains images. If you don't see images, click here to view.
Click
here to advertise in this news brief.
|
|
|
|
Free March Webinars
AST
1. Hepatitis C Treatment in Non-liver Solid Organ Transplant Recipients Tuesday, March 17, 2 p.m. EST.
Register today at www.myAST.org/T3 - free for AST members.
The recent availability of interferon-free, all-oral, antiviral drug combinations to treat of chronic hepatitis C provides an opportunity to revise management algorithms to optimize the care of non-liver transplant candidates and recipients.
2. Monitoring the Alloresponse Before and After Transplantation: Tuesday, March 31, 2 p.m. EST.
Register today at www.myAST.org/T3 - free for AST members.
Review the available data on pre- and post-transplant immune monitoring and how incorporating specific tests may help us diagnose, predict, and better treat our transplant recipients.
3. FQAPI Worksheet Webinar March 11 at Noon EST
Join us and ASTS as we host a monthly educational webinar series designed and presented by the Centers for Medicare and Medicaid Services. This series will detail all elements of Quality Assurance and Performance Improvement (QAPI). The next webinar is Wednesday, March 11 and features an overview of the FQAPI worksheet utilized by CMS surveyors.
Webinars are free to all: membership in AST or ASTS is not required. All webinars will be broadcast live, and the recordings will be made available on demand following the air date. View complete details and register at www.myAST.org/FQAPI.
The content of this presentation is determined independently by CMS: neither the AST nor ASTS have input on the content. We appreciate CMS providing this information to the transplant community and so we are facilitating that process, but that should not be construed as any endorsement of the content by either organization.
|
|
Share this article:
    |
|
|
|
UPCOMING EVENTS IN TRANSPLANTATION
|
Mark Your Calendar! AST Town Hall and Excellence in Transplantation Reception at ATC
AST
We invite you and all AST members to attend the AST Town Hall meeting at ATC on Monday, May 4 at 5:45 p.m. This meeting provides a forum for open discussion between AST membership and leadership about key issues impacting our society and field of transplantation. In addition, we'll announce the Board of Directors election results, honor AST volunteer leaders, and award the 2015 research grants. Immediately following the Town Hall meeting, join friends and colleagues for the Excellence in Transplantation Reception.
PRODUCT SHOWCASE
 |
|
The UCLA Immunogenetics Center (UIC) provides comprehensive testing for organ and tissue transplantation. Transplant testing has a long history at UCLA. HLA typing was pioneered here in the 1960's. The development of the microcytoxicity test in 1964 marked the beginning of international testing and standardization of HLA typing. The UCLA Immunogenetics Center has retained its leadership position in HLA research, and in the development of accompanying diagnostic testing. MORE
|
|
OPTN/SRTR 2013 Annual Data Report: Liver
American Journal of Transplantation
During 2013, 10,479 adult candidates were added to the liver transplant waiting list, compared with 10,185 in 2012; 5921 liver transplants were performed, and 211 of the transplanted organs were from living donors. As of Dec. 31, 2013, 15,027 candidates were registered on the waiting list, including 12,407 in active status. The most significant change in allocation policy affecting liver waitlist trends in 2013 was the Share 35 policy, whereby organs from an entire region are available to candidates with model for end-stage liver disease scores of 35 or higher.
OPTN/SRTR 2013 Annual Data Report: Intestine
American Journal of Transplantation
Despite improvements in medical and surgical treatment of intestinal failure over the past decade, intestine transplant continues to play an important role. Of 171 new patients added to the intestine transplant waiting list in 2013, 49 percent were listed for intestine-liver transplant and 51 percent for intestine transplant alone or with an organ other than liver. The pretransplant mortality rate decreased dramatically over time for all age groups, from 30.3 per 100 waitlist years in 2002-2003 to 6.9 for patients listed in 2012-2013.
|
Raptor's mission is to develop and commercialize life-altering therapeutics that treat rare, debilitating, and often fatal diseases.
LEARN MORE
|
|
To find out how to feature your company in the AST eNewsletter and other advertising opportunities, Contact Tom Crist at 972-402-7724.
MORE
|
|
Serum sodium and survival benefit of liver transplantation
Liver Transplantation
Hyponatremia is associated with elevated wait-list mortality among end-stage liver disease candidates for liver transplantation (LT). However, the effect of low serum sodium on the survival benefit of LT has not been examined. We sought to determine whether pretransplant hyponatremia is associated with an altered LT survival benefit. Data were obtained from the Scientific Registry of Transplant Recipients. The study population consisted of adults (age ≥ 18 years) placed on the waiting list for LT between Jan. 1, 2005 and Dec. 31, 2012.
Renal function in de novo liver transplant recipients receiving different prolonged-release tacrolimus regimens—the DIAMOND study
American Journal of Transplantation
DIAMOND: multicenter, 24-week, randomized trial investigating the effect of different once-daily, prolonged-release tacrolimus dosing regimens on renal function after de novo liver transplantation. Arm 1: prolonged-release tacrolimus (initial dose 0.2mg/kg/day); Arm 2: prolonged-release tacrolimus (0.15–0.175mg/kg/day) plus basiliximab; Arm 3: prolonged-release tacrolimus (0.2mg/kg/day delayed until Day 5) plus basiliximab. All patients received MMF plus a bolus of corticosteroid (no maintenance steroids).
HLA epitopes as viewed by antibodies: What is it all about?
American Journal of Transplantation via PubMed
The need for new approaches to define HLA antibodies, in the context of organ transplantation, is intensely debated among HLA professionals. In this review, we sought to provide background and perspective to current understanding of the immunogenicity of HLA mismatches with respect to the humoral alloimmune response and the definition of B cell epitopes.
Missed last week's issue? See which articles your colleagues read most.
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
